| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC2140 |
| Trial ID | NCT04011293 |
| Disease | Refractory Hematologic Cancer |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CNCT19|inaticabtagene autoleucel |
| Location approved | China |
| Phase | Early_Phase1 |
| Recruitment status | Unknown |
| Title | A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies |
| Year | 2019 |
| Country | China |
| Company sponsor | Shandong University |
| Other ID(s) | HY001003 |
| Cohort 1 | |||||||||||
|
|||||||||||